Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET. - Wikidata - wikimedia - TriplyDB

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

http://www.wikidata.org/entity/Q36963554

about

Development of 99mTc-radiolabeled nanosilica for targeted detection of HER2-positive breast cancer.Review: Receptor Targeted Nuclear Imaging of Breast Cancer.99m Tc-anti-epidermal growth factor receptor nanobody for tumor imaging.Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer.Prognostic importance of peritoneal lesion-to-primary tumour standardized uptake value ratio in advanced serous epithelial ovarian cancer.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.

P2860

Q33649880-A11DE014-030C-4C1A-8B1B-5150ED6DCA8E Q37690662-AFFDEA36-0E54-4A1E-8DDC-67A02C658046 Q38744686-AA5115B0-97A3-4BB3-8CE4-6CA059BE2A79 Q39233197-AB708DB2-5347-4DDE-929D-FFE95A61A8D3 Q41514209-CB0F4C1A-2F10-4199-B26C-C52002556B3D Q47279109-039E6679-8A40-4FB0-8B06-7F44FA0A2CC3 Q50068024-D968293F-0AA9-453C-9018-C8C91F807DA3 Q51740406-92E82223-C639-4941-9BA9-F3AC1599E1C8 Q52098663-CA5F296B-1D10-45F9-A222-90660C3F814F Q52657511-4E7733A5-EEB0-43AC-B953-C426483AC0BF

P2860

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

http://www.wikidata.org/entity/Q36963554

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Preclinical Evaluation of 18F- ...... ptor Expression by Immuno-PET.

@en

type

label

Preclinical Evaluation of 18F- ...... ptor Expression by Immuno-PET.

@en

prefLabel

Preclinical Evaluation of 18F- ...... ptor Expression by Immuno-PET.

@en

P1433

Q36963554-E48ECFD0-6222-446F-AACC-159B12023E86

P1476

Q36963554-928CA84E-545A-482B-8F9A-E0CB87C32D59

P2093

Q36963554-0EB7D4CA-4655-4BD0-9C22-4A3F2AD31C55

Q36963554-1AE0D15B-788F-4C70-97BD-CD778F69908C

Q36963554-3D202562-4D69-44D4-8FA3-1CA757FD20F3

Q36963554-5F6078D5-6E7A-483C-B36B-8FDEE994B80F

Q36963554-75F4C805-23FF-45B4-BBC9-9285FC1AA41B

Q36963554-80078BF7-A3D5-4B11-B49C-DC745BFEF213

Q36963554-9B93A301-DF0A-4841-8E9B-5D31B5AD395C

P2860

Q36963554-041677DA-FEA1-481B-AF42-4FD16D4DA1B9

Q36963554-05E6F115-95D0-4BE8-8C77-64B593957314

Q36963554-0A57798C-A759-4E7C-BF1E-B5E0A7E58AD3

Q36963554-14BFA473-1D8B-492B-9B78-87BA468C4ACD

Q36963554-26025668-3CDE-4294-8B38-AE389D21AD5B

Q36963554-2D7AE1F2-EC57-4243-9F1F-B0479BE922CA

Q36963554-334AE690-5830-45F5-BC1C-BB1A22552C32

Q36963554-3893F1DA-6094-41BD-A6C7-687EDD85007C

Q36963554-40E3C0AD-47BD-4AA4-A4BE-5420B88E9526

Q36963554-5284CEA6-9A68-46FF-9BBE-90CCAFC9872E

P304

Q36963554-46C400D6-B5FD-4E52-B8F2-1D468B17E029

P31

Q36963554-BE277679-360E-45EC-AA30-343586BBBAB7

P356

Q36963554-9B3046A2-965E-4AFD-A752-16A1516880FA

P407

Q36963554-859F5AB1-0B3C-4FEC-B7E0-1B6147510DA4

P433

Q36963554-82D2D8C1-A428-4489-8603-789EA543F094

P478

Q36963554-F545888E-B7F8-4E50-A36B-A810DB0267EF

P50

Q36963554-11D385A8-7FA4-40A0-9C28-97D55CBC1672

P577

Q36963554-40837945-3BEA-40F0-AEA8-2CF181BCF97D

P698

Q36963554-3420B720-2BBB-4180-829B-D86A4ABCE002

P932

Q36963554-A141C532-AA8B-49DF-B5A9-121A736A4924

P356

JNUMED.115.171306

P1433

The Journal of Nuclear Medicine

P1476

Preclinical Evaluation of 18F- ...... eptor Expression by Immuno-PET

@en

P2093

Darryl McDougald

http://www.w3.org/2001/XMLSchema#string

Douglas Weitzel

http://www.w3.org/2001/XMLSchema#string

Eftychia Koumarianou

http://www.w3.org/2001/XMLSchema#string

Ganesan Vaidyanathan

http://www.w3.org/2001/XMLSchema#string

Jaeyeon Choi

http://www.w3.org/2001/XMLSchema#string

Michael R Zalutsky

http://www.w3.org/2001/XMLSchema#string

Takuya Osada

http://www.w3.org/2001/XMLSchema#string

P2860

18F-Labeled Peptides: The Future Is Bright

Cancer treatment and survivorship statistics, 2014

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

Overview of breast cancer collaborative stage data items--their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010.

Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling

Trastuzumab-induced cardiac dysfunction: A 'dual-hit'

Noninvasive imaging of immune responses.

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

P304

967-973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.115.171306

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Herbert Kim Lyerly

P577

2016-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26912425

http://www.w3.org/2001/XMLSchema#string

P932

4891273

http://www.w3.org/2001/XMLSchema#string